Study reveals how well saudi doctors follow safety rules for common arthritis drug
NCT ID NCT06714461
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether healthcare professionals in Saudi Arabia are aware of and follow safety measures for the drug leflunomide, used for rheumatoid and psoriatic arthritis. Researchers surveyed 302 doctors and pharmacists to see if they received and read safety materials, and if they counseled patients and ordered proper lab tests. The goal was to assess how well the extra safety steps are working, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sanofi-Aventis
Chilly-Mazarin, 91380, France